Probiotics in the clinical course in patients with critical care illness to modulate gut microbiota composition



<u>Santanu Das¹, Kanukuntla Saikrishna², Daizee Talukdar¹ Animesh Ray², Bhabatosh Das ¹*</u> Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, India, Department of Medicine, All India Institute of Medical Science Email:- santanudas@thsti.res.in

INTRODUCTION

RESULTS and DISCUSSION



Highlights

- Differences in alpha diversity of gut microbiota between probiotic-treated and non-treated groups were not statistically significant

Ventilator-Associated Pneumonia (VAP) is a nosocomial infection that affects patients who rely on mechanical ventilation, which increases patient morbidity and mortality and increases overall treatment cost. Through this prospective observational study we aim to investigate the effects of probiotics VAP and its relationship with clinical outcomes in mechanically ventilated patients.

- Longitudinal analysis of commensal and pathogenic taxa at three different timepoints revealed no significant differences in abundance among taxa in first two timepoints
- Significant increase of *Streptococcus* observed in probiotic treated group at T₃ (p=0.03)
- At species level analysis, *Lactobacillus* paracasei *Streptococcus* and *thermophillus* (contained in VSL#3®) were significantly higher in probiotic-treated group
- L. higher overall in paracasei was sequential probiotic whereas group, thermophillus with increase *S.* OT



Figure 1 Taxa tree depicting the organization of identified taxa from phylum through genus level for nanopore reads. On the lower right-hand side is the color scale, the color intensity of the nodes represents the abundances of taxa.



METHODS

- Cohort Size (n) = 169, Included = 86, Excluded = 83
- VSL#3[®]: 112.5 billion CFU/cap)
- Dose of 6 capsule/day
- Subject completed the study ; 22 (probiotics treated) and 13 (control)
- Faecal samples were collected at three intervals

Collection of faecal samples at three time intervals and sent to laboratory T₂ VAP patients Metagenomic DNA extraction and Library preparation . 200 -Axis1 [24.1 %] Position in read (bp Read QC (Q > 30 retained) Diversity and Taxonomic analysis NGS in Illumina/ONN Probiotic treated Created in BioRender.com bio in R environment Without Probiotic

Figure 2: Probiotic treated group shows a significant increase in Lacticaseibacillus paracsei at all three timepoints, demonstrating a clear contrast to the unchanging levels in the control group (*<0.01).

Figure 3: Probiotic treated group shows a significant increase in Streptococcus thermophilus at all three timepoints, demonstrating a clear contrast to the unchanging levels in the control group(*<0.05, **<0.01).

CONCLUSIONS

- Axis1 [24.1 %] T0_P T0_WP T1 P
 - Elevated abundance of *Lactobacillus paracasei* and thermophillus (contained Streptococcus in VSL#3[®]) observed in the probiotic-treated group
 - Higher overall abundance of *L. paracasei* in the probiotic group
 - *thermophillus* with Sequential increase of *S.* progression of probiotic dose
 - Results suggest probiotic treatment may result in alterations in favorable microbiome gut composition



T1_WP
T2_P
T2_WP

- Sequence done in Illumina MiSeq and Oxford nanopore platform
- Sequence QC by FastQ
- Taxonomy assigned using SILVA138.1 and Kraken2
- Diversity analysis in vegan and phyloseq packages

Figure 4: Principal coordinate analysis plot (PcoA) of the gut microbiome. Each dot represents a particular sample, which is color coded based on the time points. A) Between probiotic treated and without probiotic B) Between the time-points of probiotic treatment.

- No significant benefit observed in decreasing incidence of ventilator acquired pneumonia, reducing length of hospital stay.
- Further investigation into optimal dosages and frequencies of probiotics required to enhance clinical outcomes

ACKNOWLEDGEMENT

The authors also extends their gratitude to Dr. Pramod Garg, Executive Director, THSTI for his support and encouragement. This work was funded by the Indian Council of Medical Research (ICMR), New Delhi Funding Agency under Grant number 5/9/1208/2019-Nut, Dt. 16.09.2019and Department of Biotechnology, Government of India.

Created with BioRender Poster Builder